Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.69 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 4/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | HTT | P42858 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14991641 | 0.97 | L3MBTL3 (0.74) | L3MBTL4L3MBTL3L3MBTL1HPGDSMN1; SMN2 | |
| SCHEMBL18734159 | 0.95 | L3MBTL3 (0.72) | L3MBTL4L3MBTL3L3MBTL1HPGDSMN1; SMN2 | |
| SCHEMBL5909234 | 0.87 | L3MBTL4 (0.59) | L3MBTL4L3MBTL3L3MBTL1HPGDSMN1; SMN2 | |
| SCHEMBL27402476 | 0.85 | L3MBTL4 (0.60) | L3MBTL4L3MBTL3L3MBTL1HPGDSMN1; SMN2 | |
| SCHEMBL2376190 | 0.85 | L3MBTL1 (0.60) | L3MBTL4L3MBTL3L3MBTL1HPGDSMN1; SMN2 | |
| SCHEMBL30961632 | 0.85 | L3MBTL4 (0.60) | L3MBTL4L3MBTL3L3MBTL1HPGDSMN1; SMN2 | |
| SCHEMBL1558959 | 0.85 | ALDH1A1 (0.72) | L3MBTL4L3MBTL3L3MBTL1HPGDSMN1; SMN2 | |
| SCHEMBL3030683 | 0.85 | L3MBTL3 (0.79) | L3MBTL4L3MBTL3L3MBTL1ALDH1A1HSD17B10 | |
| SCHEMBL12751719 | 0.83 | L3MBTL4 (0.69) | L3MBTL4L3MBTL3L3MBTL1HPGDSMN1; SMN2 | |
| SCHEMBL26426187 | 0.83 | L3MBTL4 (0.58) | L3MBTL4L3MBTL3L3MBTL1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11066393-B2 | Indolin-2-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-11066393-B2 | Indolin-2-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-20200299278-A1 | INDOLIN-2-ONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-09-24 | — | — | US | disclosed |
| US-20200299278-A1 | INDOLIN-2-ONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-09-24 | — | — | US | disclosed |
| US-10710985-B2 | Indolin-2-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-10710985-B2 | Indolin-2-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-07-14 | — | — | US | disclosed |
| EP-3371168-B1 | INDOLIN-2-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2020-05-27 | — | — | EP | disclosed |
| EP-3371168-B1 | INDOLIN-2-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2020-05-27 | — | — | EP | disclosed |
| EP-3371168-A1 | INDOLIN-2-ONE DERIVATIVES | H. Hoffnabb-La Roche Ag (CH) | 2018-09-12 | — | — | EP | disclosed |
| US-20180251449-A1 | INDOLIN-2-ONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-09-06 | — | — | US | disclosed |
| US-20090029905-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
| US-20090029905-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
| US-20090018112-A1 | Compounds and Uses Thereof | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | US | disclosed |
| US-20080318925-A1 | Compounds and Uses Thereof - 849 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| WO-2008155573-A1 | CINNOLINE COMPOUNDS FOR USE IN THE TREATMENT OF SCHIZOPHRENIA | ASTRAZENECA AB (SE) | 2008-12-24 | — | — | WO | disclosed |
| US-7465795-B2 | Compounds and uses thereof | ASTRAZENECA AB (SE) | 2008-12-16 | — | — | US | disclosed |
| EP-1966158-A1 | SUBSTITUTED CINNOLINE DERIVATIVES AS GABAA-RECEPTOR MODULATORS AND METHOD FOR THEIR SYNTHESIS | AstraZeneca AB (SE) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007073283-A1 | SUBSTITUTED CINNOLINE DERIVATIVES AS GABAA-RECEPTOR MODULATORS AND METHOD FOR THEIR SYNTHESIS | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
| US-20070142328-A1 | Compounds and Uses Thereof | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | US | disclosed |
| US-20070142382-A1 | Compounds and Uses Thereof | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029905-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | GCK, GCKR, GK | L3MBTL4 4394/4885L3MBTL3 4556/4885L3MBTL1 4135/4885 |
| US-20070142328-A1 | Compounds and Uses Thereof | MAPT, BDNF, PYGB | L3MBTL4 3436/4885L3MBTL3 3626/4885L3MBTL1 2822/4885 |
| US-10710985-B2 | Indolin-2-one derivatives | GRIN2B, GRIN2A, TPH2 | L3MBTL4 3522/4885L3MBTL3 3527/4885L3MBTL1 2171/4885 |
| US-20070142382-A1 | Compounds and Uses Thereof | MAPT, BDNF, PYGB | L3MBTL4 3436/4885L3MBTL3 3626/4885L3MBTL1 2822/4885 |
| US-20180251449-A1 | INDOLIN-2-ONE DERIVATIVES | GRIN2B, GRIN2A, TPH2 | L3MBTL4 3522/4885L3MBTL3 3527/4885L3MBTL1 2171/4885 |
| US-20090018112-A1 | Compounds and Uses Thereof | MAPT, BDNF, PYGB | L3MBTL4 3436/4885L3MBTL3 3626/4885L3MBTL1 2822/4885 |
| US-11066393-B2 | Indolin-2-one derivatives | GRIN2B, GRIN2A, TPH2 | L3MBTL4 3522/4885L3MBTL3 3527/4885L3MBTL1 2171/4885 |
| US-20200299278-A1 | INDOLIN-2-ONE DERIVATIVES | GRIN2B, GRIN2A, TPH2 | L3MBTL4 3522/4885L3MBTL3 3527/4885L3MBTL1 2171/4885 |
| US-20080318925-A1 | Compounds and Uses Thereof - 849 | COMT, UGT1A9, BACE1 | L3MBTL4 3329/4885L3MBTL3 4162/4885L3MBTL1 3865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.